Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Edward Lee Carter: Are All DOACs Truly Interchangeable in Real-World Practice?
Edward Lee Carter/LinkedIn
Mar 26, 2026, 15:47

Edward Lee Carter: Are All DOACs Truly Interchangeable in Real-World Practice?

Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared a post on LinkedIn:

”Apixaban vs Rivaroxaban — are we starting to see separation?

The COBBRA trial (March 2026) adds another important data point to a question many of us deal with daily:

Are all DOACs truly interchangeable in real-world practice?

COBBRA compared Apixaban vs Rivaroxaban in a contemporary patient population, focusing on both effectiveness and bleeding risk.

Key takeaway (high-level):
Apixaban demonstrated a more favorable bleeding profile, while maintaining comparable effectiveness for thromboembolic prevention.

That signal is not entirely new—but it’s becoming more consistent.

Why this matters in practice:

We often think of DOACs as a class.
But clinically, they behave more like related—but distinct—tools.

What COBBRA reinforces:

  • Bleeding risk is not uniform across DOACs
  • Patient selection still matters (renal function, age, weight, comorbidities)
  • ‘One-size-fits-all anticoagulation’ continues to fall short

Practical considerations:

Apixaban

  • Lower observed bleeding rates in multiple datasets
  • BID dosing (may improve peak/trough stability)

Rivaroxaban

  • Once-daily dosing (adherence advantage for some patients)
  • Still a strong, guideline-supported option

The bigger picture:

We’re seeing convergence from:

  • RCTs
  • Real-world data
  • Now additional comparative trials like COBBRA

And the trend is fairly consistent:

  • Apixaban often emerges with a bleeding advantage
  • Effectiveness remains comparable

For clinicians:

This isn’t about declaring a ‘winner.’

It’s about refining decisions at the bedside.

Matching the right anticoagulant to the right patient
Balancing bleeding risk vs adherence vs comorbidity profile

Bottom line:
DOACs may share a mechanism – but they do not share identical clinical outcomes.”

Edward Lee Carter: Are All DOACs Truly Interchangeable in Real-World Practice?

Stay updated with Hemostasis Today.

Apixaban DOACs Edward Lee Carter Headlines Health Hematology Hemostasis Hemostasis News Hemostasis Today Rivaroxaban thrombosis
NewsFeed